COVID–19の第1波への対応についてのJAAM全国調査(JAAM nationwide survey on the response to the first wave of COVID–19 in Japan): ~第2部:医療機関はどのように乗り越えたのか,今後どう備えるべきか~(–Part II: How did medical institutions overcome the first wave and how should they prepare for the future? –)

COVID-19の第1波への対応についてのJAAM全国调查(JAAM全国调查,关于日本第一波COVID-19的应对情况): ~第2部:医疗机关はどのように乘り越えたのか,今后どう备えるべきか~(–第二部分:医疗机构如何度过第一波浪潮,如何应对未来?–)

阅读:1

Abstract

Aim: To investigate and clarify the surge capacity of staff/equipment/space, and patient outcome in the first wave of coronavirus disease (COVID–19) in Japan. Methods: We analyzed questionnaire data from the end of May 2020 from 180 hospitals (total of 102,578 beds) with acute medical centers. Results: A total of 4,938 hospitalized patients with COVID–19 were confirmed. Of 1,100 severe COVID–19 inpatients, 112 remained hospitalized and 138 died. There were 4,852 patients presumed to be severe COVID–19 patients who were confirmed later to be not infected. Twenty–seven hospitals (15% of 180 hospitals) converted their intensive care unit (ICU) to a unit for COVID–19 patients only, and 107 (59%) had to manage both severe COVID–19 patients and others in the same ICU. Restriction of ICU admission occurred in one of the former 27 hospitals and 21 of the latter 107 hospitals. Shortage of N95 masks was the most serious concern regarding personal protective equipment. As for issues that raised ICU bed occupancy, difficulty undertaking or progressing rehabilitation for severe patients (42%), and the improved patients (28%), long–lasting severely ill patients (36%), and unclear isolation criteria (34%) were mentioned. Many acute medicine physicians assisted regional governmental agencies, functioning as advisors and volunteer coordinators. Conclusion: The mortality rate of COVID–19 in this study was 4.1% of all hospitalized patients and 12.5% (one in eight) severe patients. The hospitals with dedicated COVID–19 ICUs accepted more patients with severe COVID–19 and had lower ICU admission restrictions, which could be helpful as a strategy in the next pandemic.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。